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The epidermal growth factor (EGF) family and its re-
ceptors regulate normal and cancerous epithelial cell
proliferation, a process that could be suppressed by an-
ti-receptor blocking antibodies. Polypeptide elongation
factor-1a (EF-1a) is a multifunctional protein whose lev-
els are positively correlated with the proliferative state
of cells. To identify genes, whose expression may be
modulated by anti-receptor blocking antibodies, we per-
formed a differential display screening and isolated dif-
ferentially expressed cDNAs. Isolates from one clone
were 100% identical to human EF-1a. Both EGF and
heregulin-b1 (HRG) induced EF-1a promoter activity
and mRNA and protein expression. Growth factor-medi-
ated EF-1a expression was effectively blocked by pre-
treatment with humanized anti-EGF receptor antibody
C225 or anti-human epidermal growth factor receptor-2
(HER2) antibody herceptin. Mutants and pharmacolog-
ical inhibitors of p38MAPK and MEK, but not phosphati-
dylinositol 3-kinase, suppressed both constitutive and
HRG-induced stimulation of EF-1a promoter activity in
MCF-7 cells. Deletion analysis of the promoter suggested
the requirement of the 2393 to 2204 region for growth
factor-mediated transcription of EF-1a. Fine mapping
and point mutation studies revealed a role of the SP1
site in the observed HRG-mediated regulation of the
EF-1a promoter. In addition, we also provide new evi-
dence to suggest that HRG stimulation of the EF-1a pro-
moter involves increased physical interactions with
acetylated histone H3 and histone H4. These results sug-
gest that regulation of EF-1a expression by extracellular
signals that function through human EGF receptor fam-
ily members that are widely deregulated in human can-
cers and that growth factor regulation of EF-1a expres-
sion involve histone acetylation.
Growth factors and their receptors play an important role in
the regulation of epithelial cell growth. Abnormalities in the
expression, structure, or activity of proto-oncogene products
contribute to the development and the pathogenesis of cancer.
For example, the human epidermal growth factor receptor
(HER1)1 is overexpressed in a number of epithelial tumor cells
(1). HER2, the second member of the HER family, shares ex-
tensive sequence homology with the tyrosine kinase domain of
HER1 (1, 2) and is overexpressed and/or amplified in a number
of human malignancies, including breast, ovarian, colon, lung,
prostate, and cervical cancers. Recently, HER3 and HER4 have
been added to the family, as they share sequence homology
with the tyrosine kinase domain of HER1 (2). Regulation of
these receptor family members is complex, and they can be
transactivated in a ligand-dependent manner. For example,
binding of heregulin-b1 (HRG) to HER3 or HER4 can activate
HER2 receptor as a result of HER2/HER3 or HER4/HER2
heterodimeric interactions (3, 4). HER1 and HER2 have been
shown to induce transformation in recipient cell, possibly be-
cause of excessive activation of signal transduction pathways.
In contrast, transformation by HER3 or HER4 requires the
presence of HER1 or HER2 (3, 4).
Since growth factors regulate the proliferation of cancer cells
by activating receptors on the surface of the cells, one approach
to controlling cell proliferation is to use anti-receptor blocking
monoclonal antibodies that interfere with growth factor recep-
tor-mediated autocrine/paracrine growth stimulation. The hu-
manized antibody C225 against the EGF receptor (EGFR)
blocks binding of ligand and prevents ligand-induced activation
of receptor tyrosine kinase (5, 6). C225 is currently being used
in phase IIA multicenter clinical trials alone and in combina-
tion with chemotherapy or radiation to treat to patients with
head and neck, lung, or prostate carcinomas (7–9). Similarly,
the humanized form of anti-HER2 monoclonal antibody HCT
(herceptin) inhibits the growth of breast cancer cells overex-
pressing HER2 (10, 11) and is currently being used as an
effective drug against some forms of breast cancer (12). Anti-
receptor antibodies are known to inhibit many processes, in-
cluding mitogenesis, cell cycle progression, invasion and me-
tastasis, angiogenesis, and DNA repair.
Mitogenic growth factors stimulate protein synthesis in eu-
karyotic cells. Polypeptide elongation factor-1a (EF-1a) is a
ubiquitously expressed protein that plays a key role in the
elongation cycle during translation. EF-1a forms a complex
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with aminoacyl-tRNA and GTP that transfers the aminoacyl-
tRNA group to the 80 S ribosome and hydrolyzes GTP (13).
EF-1a is also involved in cytoskeleton reorganization (14, 15)
and proliferation (16). It can regulate embryogenesis (17), actin
bundling, and microtubule severing and is associated with the
centrosome and mitotic machinery (14, 18, 19). EF-1a is also
one of the actin-associated activators of phosphatidylinositol
4-kinase, which regulates the levels of phosphatidylinositol
4-phosphate and phosphatidylinositol 4,5-bisphosphate (20).
These phospholipids regulate the capping of actin filaments by
actin-binding protein (18). In brief, EF-1a regulates cellular
functions that are both dependent on and independent of trans-
lational controls.
Next only to actin, EF-1a is the most abundant protein in
normal cells, accounting for 1–2% of total protein. Regulation of
its levels may be important for normal cell function; rapidly
growing cells usually exhibit a large increase in their EF-1a
mRNA levels (21); overexpression of EF-1a correlates with
metastasis (22); and EF-1a mRNA levels decrease during mu-
rine erythroleukemic cell differentiation (23). EF-1a expression
can be regulated at both the transcriptional and post-transcrip-
tional levels (24, 25). EF-1a mRNA levels have been shown to
be up-regulated by oncogenes and induced by phytohemagglu-
tinin in human blood lymphocytes (22, 26). In addition, over-
expression of EF-1a in fibroblasts leads to increased suscepti-
bility to oncogenic transformation (27). In addition to its
predominant cytoplasmic presence, EF-1a has been reported in
the nucleus (28) where it binds to RNA polymerase (29). Re-
cently, EF-1a has been shown to be physically associated with
the novel zinc finger protein ZPR1 in A-431 cells and to be
translocated to the nucleus in an EGF-dependent manner (30).
Furthermore, insulin can regulate translational elongation ac-
tivity of EF-1a by regulating its phosphorylation by multipo-
tential S6 kinase (31–33). Yet, despite knowledge of these cel-
lular functions, the possible regulation of EF-1a by the EGF
family of growth factors and by therapeutic anti-receptor anti-
bodies remains unexplored.
To identify genes whose expression may be down-regulated
by anti-receptor blocking antibodies, presumably owing to li-
gand-induced activation of receptor tyrosine kinase and/or in-
terference of receptor-associated functions, we used differential
display approach to isolate differentially expressed cDNAs. We
report that one of these clones had 100% identity with human
elongation factor-1a (EF-1a). Both EGF and HRG induced
EF-1a promoter activity and mRNA and protein expression
that could be effectively blocked by pretreatment with anti-
receptor monoclonal antibodies. Our results also suggest in-
volvement of specific signaling pathways in the base-line reg-
ulation of EF-1a transcription. In addition, we also provide new
evidence to suggest that HRG stimulation of EF-1a promoter
requires the SP1 site and that the EF-1a promoter undergoes
histone acetylation in response to HRG.
EXPERIMENTAL PROCEDURES
Cell Cultures and Reagents—Human breast cancer cells MCF-7,
MDA-MB468, BT-474, SK-BR-3, MDA-MB231, and MDA-MB435 (34),
mouse NIH3T3 cells transfected with human EGFR (HER14 cells, Fan
et al. (35)), and vulvar carcinoma A-431 cells (6) were maintained in
Dulbecco’s modified Eagle’s medium/F-12 (1:1) supplemented with 10%
fetal calf serum. Recombinant HRG-b1 was purchased from Neomark-
ers Inc. Anti-vinculin antibody and recombinant EGF were purchased
from Sigma.
Differential Display and Cloning of EF-1a cDNA—Differential dis-
play was performed according to the method described in Ref. 36. In
brief, MDA-MB435 and MDA-MB231 cells were treated with or without
C225 or herceptin. Total RNA was isolated using Trizol reagent (Life
Technologies, Inc.). Total RNA was digested with RNase-free DNase
(Promega) and purified by phenol/chloroform extraction. First strand
cDNA was synthesized by reverse transcriptase reaction containing 200
ng of total RNA using four different degenerate anchored oligo(dT)
primer set (dT12VA, dT12VG, dT12VC, dT12VT; Operon Technologies
Inc.). Reactions were performed in a 20-ml volume using Moloney mu-
rine leukemia virus reverse transcriptase (Promega). Amplification of
cDNA fragments was performed using 2 ml of the cDNA in reaction
buffer containing 2 ml of 103 PCR buffer, 10 mCi of a-35S-dATP, dNTPs
(2 mM), 1 unit of Taq polymerase (Roche Molecular Biochemicals), the
same 39-degenerate oligo(dT) primer, and 1 of the 10 59-orbitary decam-
ers (OP-26–01 to OP-26–10, Operon Technology, Inc.). PCR cycles were
as follows: denaturation 95 °C for 5 min, 40 cycles at 94 °C for 30 s,
40 °C for 2 min, 72 °C for 30 s with a final extension of 72 °C for 10 min.
PCR products were separated on a 6% polyacrylamide gel and devel-
oped by autoradiography. Bands of interest were excised, extracted, and
reamplified with same set of primers. Amplified DNA was separated on
an agarose gel, and bands were purified and cloned into PCR2.1 vector
using Topocloning kit (Invitrogen). Five to ten independent clones were
isolated, miniprepared, and sequenced at the M. D. Anderson Cancer
Core facility. Sequences were compared with GenBankTM sequences
using BLAST search.
Construction of EF-1a Promoter Deletion Constructs—Construction
of deletion constructs pEF (construct numbers 1–7) was described (37).
Sub-fragmentation of the insert of construct 6 was done using restric-
tion sites HindIII/SphI, HindIII/StyI, and AvaII/SphI. Cloning of blunt-
ended fragments into the XbaI site of pBLCAT5 (38) yielded constructs
8, 9, and 12, respectively. The mutations in construct 9 were made using
the QuickChange kit (Stratagene) according to the instructions.
Cell Extracts, Immunoblotting, and Immunoprecipitation—To pre-
pare cell extracts, cells were washed three times with phosphate-buff-
ered saline and lysed in buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl,
0.5% Nonidet P-40, 100 mM NaF, 200 mM NaVO5, 1 mM phenylmethyl-
sulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin) for 15 min on
ice. The lysates were centrifuged in an Eppendorf centrifuge at 4 °C for
15 min. Cell lysates containing equal amounts of protein were resolved
by SDS-PAGE, transferred to nitrocellulose, and probed with the ap-
propriate antibodies. An equal number of cells were metabolically la-
beled for 4–8 h with 100 mCi/ml [35S]methionine in methionine-free
medium containing 2% dialyzed fetal bovine serum in the absence or
presence of indicated treatments. Cell extracts containing equal trichlo-
roacetic acid-precipitable counts were immunoprecipitated with the
desired antibody, resolved on SDS-PAGE, and analyzed (34).
Northern Hybridization—Total cytoplasmic RNA was isolated using
the Trizol reagent (Life Technologies, Inc.), and 20 mg of RNA was
analyzed by Northern hybridization using a 1.8-kilobase pair cDNA
fragment of human EF1-a. rRNA (28 S and 18 S) was used to assess the
integrity of the RNA, and for RNA loading and transfer control, the
blots were routinely reprobed with glyceraldehyde-3-phosphate dehy-
drogenase cDNA.
Transfection and Promoter Assays—Cells were split in 100-mm tis-
sue culture dishes (Falcon) 24 h before transfection. Subconfluent cells
were transiently transfected with pEFD1090CATSp1 or with other
constructs as needed or control pSVb-Gal vector using LipofectAMINE
method (Life Technologies, Inc.). After 5 h of transfection, medium was
changed to Dulbecco’s modified Eagle’s medium containing 10% serum.
After 24 h, cultures were shifted to 0% serum (for growth factor treat-
ment) or 2% serum (for antibody treatment) for 12 h before harvesting.
CAT activity was measured 48 h after transfection using a CAT assay
kit (Promaga) (39). When indicated, cells were treated with HRG or
EGF (30-ng/ml medium) or herceptin or C225 (50 nM final concentra-
tion). In some experiments, cells were pretreated with 20 mM PD098059
(a MEK inhibitor), 20 mM SB203580 (a p38MAPK inhibitor), and 20 mM
LY294002 (PI3K inhibitor) for 1 h before HRG treatment. Each exper-
iment was repeated two to five times and transfection efficiency varied
between 30 and 50%.
Chromatin Immunoprecipitation Assays—MCF-7 cells were split in
100-mm tissue culture dishes (Falcon). About 70% confluent dishes
were serum-starved for 24 h followed by overnight treatment with HRG
(30 ng/ml). Quantitative chromatin immunoprecipitation assay was
done as described previously (40–42) with some modifications. Approx-
imately 106 cells were treated with formaldehyde (1% final concentra-
tion) for 10 min at 37 °C to cross-link histones to DNA. The cells were
washed twice with phosphate-buffered saline, pH 7.4, containing pro-
tease inhibitor mixture (Roche Molecular Biochemicals). Cells were
lysed and sonicated as described (40). Sonicated lysate was centrifuged
for 10 min at 12,000 rpm at 4 °C. Supernatant was diluted 10-fold by
dilution buffer containing 0.01% SDS, 1.1% Triton X-100, and protease
inhibitor mixture (Roche Molecular Biochemicals). A portion (1%) of the
chromatin solution was kept to check the amount of input DNA in
different samples before immunoprecipitation. Chromatin solutions
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were precleared with 80 ml of protein A-Sepharose beads (60 mg/ml)
saturated with salmon sperm DNA and bovine serum albumin for 30
min at 4 °C before immunoprecipitating with either anti-acetylated
histone H3 or anti-acetylated H4 antibody (Upstate Biotechnology, Inc.)
at 4 °C overnight. Immunocomplexes were recovered with 60 ml of
protein A- Sepharose beads at 4 °C for 1 h. Beads were washed as
described (40) on a rotating platform before eluting the immunocom-
plexes by incubation with 400 ml of 1% SDS containing 0.1 M NaHCO3.
The elution was heated to 65 °C for 6 h to reverse the formaldehyde
cross-links. Phenol/chloroform extraction was performed, and the su-
pernatant was ethanol-precipitated (using 20 mg of glycogen as an inert
carrier). DNA was resuspended in 50 ml of 10 mM Tris, 1 mM EDTA, pH
8.0. Quantitative PCR was done with 10 ml of DNA sample restricted to
25 cycles. The EF-1a DNA sequence of the 59 primer was 59 GATTT-
GTCCCGGACTAGCGAG and of the 39 primer was 59 TCTTCTCCAC-
CTCAGTGATGACG 39. The PCR products were resolved on a 1.5%
agarose gel and stained with ethidium bromide.
RESULTS AND DISCUSSION
Identification of Human Polypeptide Elongation Factor-1a as
an Anti-receptor Antibody-regulated Gene—In an attempt to
identify genes whose expression may be modulated in human
cancer cells by anti-receptor blocking antibodies, total RNA
was isolated from two highly invasive human breast cancer cell
lines, MDA-MB435 and MDA-MB231, and treated with or
without C225 and herceptin for 10 h. Although MDA-MB435
and MDA-MB231 cells have normal levels of EGFR and HER2,
the in vitro invasive properties of these cells were inhibited by
herceptin and C225 (43). A total of 160 reactions was performed
using four 39-degenerate oligo(dT) primers and 10 59-random
primers for each antibody treatment. Analysis of gels showed
amplification of a number of bands ranging from 100 to 600
base pairs, and the majorities of the bands were of equal
intensity. By using these bands as internal control, we ana-
lyzed for the bands with differences in intensity in C225- or
herceptin-treated lanes. This analysis resulted in the identifi-
cation of five differentially expressed gene products ranging in
size from 120 to 350 base pairs. A representative portion of the
gel is shown in Fig. 1A.
Each differentially expressed gene product was amplified,
cloned, and sequenced. The resulting sequence was compared
with sequences deposited in GenBankTM. For each gene prod-
uct five clones were sequenced, and all five sequences from one
band were 100% identical to human elongation factor-1a from
1580 to 1694 (EF1a, GenBankTM accession number X16869)
(Fig. 1B). To determine whether EF-1a expression can be mod-
ulated by anti-receptor blocking antibodies C225 and herceptin
on EF-1a mRNA levels in tumor cells, we did Northern blot
hybridization using the 1.8-kilobase pair EF-1a cDNA as a
probe. Treatment of human breast carcinoma cells (SK-BR-3,
BT-474, and MDA-MB468) and vulvar carcinoma cells (A-431)
with C225 or herceptin was accompanied by a significant de-
crease in EF-1a mRNA levels (Fig. 1C).
Regulation of EF-1a mRNA Expression by Anti-receptor An-
tibodies and Growth Factors—A-431 cells, which overexpress
EGFR, are growth-stimulated by autocrine transforming
growth factor-a (TGF-a) and growth-inhibited by C225 (6). To
determine whether TGF-a is involved in the regulation of EF-
1a, we asked whether C225, which blocks TGF-a from binding
to EGFR, could down-regulate the steady-state level of EF-1a
mRNA. Treatment of A-431 cells with C225 was accompanied
by a gradual decrease in EF-1a mRNA expression (Fig. 2A).
Similarly, herceptin treatment of BT-474 cells, which overex-
press HER2, was associated with reduced expression of EF-1a
mRNA (Fig. 2B). The observed suppression was not related to
high levels of EGFR, as C225 was effective in selectively reduc-
ing EF-1a levels (but not EF-1b) in breast cancer MDA-MB231
cells, which have normal levels of EGFR and HER2 (Fig. 2C).
Since MDA-MB231 cells are known to constitutively secrete
HRG, a combinatorial ligand for HER3 and HER4 that can
transactivate EGFR and HER2, the above results raised the
possibility that EF-1a mRNA expression could be induced by
HRG. Indeed, both HRG and EGF were potent inducers of
EF-1a mRNA (but not EF-1b) in MDA-MB231 cells (Fig. 2D).
EGF regulation of EF-1a mRNA expression was confirmed
using a mouse NIH3T3 cell line (HER14) that stably expressed
FIG. 1. Identification of EF-1a as a differentially expressed
gene. A, representative differential display band patterns of control,
C225, or HCT-treated MDA-MB231 cells. Arrow indicates the band of
interest, which is down-regulated by herceptin treatment. B, sequence
of the purified bands that matches (100%) those with human EF-1a. C,
Northern blot analysis showing down-regulation of EF-1a mRNA in
herceptin- or C225-treated breast cancer cell lines. GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase.
FIG. 2. Regulation of EF-1a mRNA expression by anti-receptor
antibodies and growth factors. A–C, tumor cell lines were treated
with or without C225 or (50 nM) for the indicated times. D and E,
MDA-MB231 or HER14 cells were treated with EGF or HRG (30 nM) for
16 h. Total RNA was isolated, and EF-1a mRNA levels were detected by
Northern blot analysis. Subsequently, the blot was reprobed with a
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe.
Quantitation of mRNA is shown in the bottom panel. Results are rep-
resentative of three experiments.
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human EGFR and responded to exogenous recombinant EGF
by growth stimulation (35). EGF treatment of HER14 cells for
8 h was accompanied by a significant increase in EF-1a mRNA
levels (Fig. 2E). Taken together, these results suggest that
EF-1a mRNA levels in a number of cell types are modulated by
EGF, HRG, and anti-receptor monoclonal antibodies that in-
terfere with EGFR and HER2.
Regulation of EF-1a Protein Expression by Anti-receptor An-
tibodies and Growth Factors—Western blot analysis was per-
formed to determine whether the modulation of EF-1a mRNA
levels by growth factors and anti-receptor monoclonal antibod-
ies was associated with a corresponding modulation in the
expression of EF-1a protein. Results demonstrated that A-431
cells and human colon carcinoma DiFi cells, which have a
functional TGF-a autocrine loop (44), expressed a lower level of
the 51-kDa EF-1a protein, after C225 treatment (Fig. 3, A and
B). Similarly, herceptin inhibited EF-1a protein levels in BT-
474 cells (Fig. 3C). In contrast, treatment of MCF-7 cells with
EGF or HRG significantly increased the level of EF-1a protein
(Fig. 3D).
To validate further the modulation of EF-1a protein expres-
sion by growth factors, we examined the effects of growth
factors and anti-receptor monoclonal antibodies on the level of
newly synthesized EF-1a protein in cells metabolically labeled
with [35S]methionine. Similar to our results from Western
analysis, treatment with C225 or herceptin resulted in a reduc-
tion of 35S-labeled EF-1a protein in A-431, BT-474, and MDA-
MB231 cells (Fig. 4, A–C). In contrast, HRG treatment caused
an increase in 35S-labeled EF-1a protein in BT-474 (Fig. 4A)
and MDA-MB231 (Fig. 4D) cells and EGF in HER14 cells (Fig.
4E). The observed induction of 35S-labeled EF-1a protein by
HRG and EGF was mediated through HER2 and EGFR, as it
was effectively suppressed by herceptin and C225 (Fig. 4, A and
E). These results indicate the ability of growth factors to induce
expression of EF-1a and of growth factor receptor antibodies to
block it.
Regulation of the EF-1a Promoter by Anti-receptor Antibodies
and Growth Factors—The regulatory elements in the human
EF-1a are not completely understood. Recently, Clark and col-
leagues (37) have shown the significance of specific elements
(44), located in the first intron and also close to the TATA box,
in the regulation of EF-1a transcription. To examine the effect
of growth factor-blocking monoclonal antibodies on EF-1a pro-
moter activity, tumor cells were transfected with the EF-1a
promoter construct pEFD1090CATSp1, which contains all reg-
ulatory elements upstream of the human EF-1a TATA box
fused to the thymidine kinase promoter (37). Treatment of
A-431 and MDA-MB231 cells with C225 (Fig. 5, A and B) and
of MDA-MB231 and BT-474 cells with herceptin (Fig. 5, B and
C) resulted in a significant inhibition of EF-1a promoter-driven
reporter transcription. Conversely, exposure of HER14 cells to
EGF was accompanied by 2–4-fold stimulation of EF-1a pro-
moter-driven transcription, and EGF receptor antagonist C225
blocked the EGF-mediated stimulation of EF-1a promoter ac-
tivity (Fig. 4D). Similarly, stimulation of EF-1a promoter ac-
tivity by HRG was also suppressed by pretreatment of MCF-7
cells with herceptin (Fig. 4E).
Growth Factor Signaling and Regulation of EF-1a Promoter
Activity—Distinct signaling pathways regulate different func-
tions of growth factors. For example, HRG utilizes p38MAPK
and PI3K pathways to regulate the spreading and formation of
lamellipodia (39, 45). A careful analysis of EF-1a promoter
(GenBankTM accession number E02627) revealed several im-
portant motifs, including AP1, SP1, CREB, CRE-BP, and
NF-kB that are activated by multiple growth factor signaling
pathways. To understand the nature of growth factor signaling
pathways leading to stimulation of the EF-1a promoter, we
employed cotransfection of EF1a promoter pEFD1090CATSp1
reporter with dominant-negative tagged mutants that specifi-
cally inhibit p38MAPK and PI3K activation or dominant-nega-
FIG. 3. Anti-receptor antibodies decrease and growth factors
increase EF-1a protein level. A–C, cells were treated with C225 or
HCT for the indicated times; D, cells were treated with EGF or HRG for
16 h. Total lysates were run on SDS-PAGE and blotted with anti-EF-1a
monoclonal antibody. Anti-vinculin antibody or anti-b-actin antibody
was used as an internal control. Quantitation of the ratio of EF-1a to
b-actin is shown in the bottom panel. Results are representative of three
to five separate experiments.
FIG. 4. Regulation of newly synthesized EF-1a protein by anti-
receptor antibodies and growth factors. A–E, cells were treated
with C225 or HCT in the presence or absence of EGF or HRG for 16 h
and metabolically labeled with [35S]methionine for 10 h before harvest-
ing. Cell lysates were immunoprecipitated with an anti-EF-1a mono-
clonal antibody and analyzed by SDS-PAGE and fluorography. Results
are representative of three independent experiments.
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tive mutant of MEK (39, 45, 46). In these studies, we used HRG
as a model growth factor. Mutants of p38MAPK and MEK, but
not PI3K, suppressed both constitutive and the extent of HRG-
induced stimulation of EF-1a promoter activity in MCF-7 cells
(Fig. 6A). The observed inhibitory effects of mutants were not
due to variability in the expression levels of the transfected
genes in cells treated with or without HRG, as shown by the
expression levels of FLAG-tagged p38AF and HA-tagged Dp85
by antibodies against FLAG and HA moieties, respectively
(Fig. 6B). To confirm these findings further, we next used
pharmacological inhibitors, such as PD098059 (for MEK),
SB203580 (for p38MAPK), and LY294002 (for PI3K), and similar
results were obtained (Fig. 6C). In brief, these results sug-
gested a preferential involvement of MEK and p38MAPK, but
not PI3K, in the base-line and HRG-inducible regulation of
EF-1a promoter activity.
Stimulation of cytoplasmic kinases by growth factors leads to
phosphorylation and activation of multiple transcription fac-
tors, including c-Jun, ATF-2, NF-kB, CREB, and SP1. Since the
binding motifs for these transcription factors are present in the
EF-1a promoter (GenBankTM accession number E02627), it is
possible that a combination of these factors may be responsible
for optimal EF-1a promoter regulation. Recent studies have
shown transcriptional regulation of the human EF-1a gene by
upstream sequences, including a novel C8-stretch element.2
A Role of SP1 in HRG Regulation of EF-1a Promoter—To
understand the mechanism by which HRG mediates its effect
on EF-1a promoter, we employed a series of deletion mutants
to map the HRG-responsive regulatory region in the EF-1a
promoter. All mutants were fussed to a CAT reporter system.
Initially, we used constructs 1–6, and we examined the effect of
HRG on the EF-1a promoter activity. There was minimal effect
of the deletions from 21090 to 2393 of the EF-1a promoter on
the levels of HRG-mediated up-regulation of EF-1a (Fig. 7,
construct numbers 1–6). To delineate further the minimal re-
gion required for HRG stimulation of the EF-1a promoter, we
next used additional mutants (Fig. 7, construct numbers 8, 9,
and 12). Constructs 8 (2393 to 2204) and 9 (2313 to 2314)
responded to HRG well, whereas constructs 12 (2204 to 2127)
and 7 (2119 to 229) showed no regulation in response to HRG.2 H. F. Jørgensen and B. F. C. Clark, unpublished data.
FIG. 5. Modulation of EF-1a promoter activity by C225 and
herceptin and growth factors. Tumor cells were transiently trans-
fected with an EF-1a promoter (pEFD1090CATSp1), and CAT activity
was measured 36 h after transfection. A–C, cultures were treated with
C225 and HCT (50 nM) for 16 h before lysis. Results are representative
of two experiments. D and E, after transfection with EF-1a promoter
(pEFD1090CATSp1), HER14 and MCF-7 cells were treated with EGF
or HRG (30 nM) in the presence or absence of C225 or herceptin (50 nM)
for 16 h, and CAT activity was measured. These studies were independ-
ently repeated four times. Relative CAT activities are shown in the
bottom panels.
FIG. 6. Delineation of signaling pathways involved in ligand-
induced stimulation of EF-1a promoter activity. A, MCF-7 cells
were transiently transfected with a full-length EF-1a promoter
(pEFD1090CATSp1) in the absence or presence of dominant-negative
mutants of MEK, p38MAPK, and PI3K. One set of cultures was treated
with or without HRG for 16 h before assaying for CAT activity. Quan-
titation of CAT activity is shown as fold induction of CAT reporter
activity by HRG treatment over the control culture for each mutant
group. B, Western blot analysis of expression of FLAG-tagged p38MAPK
and HA-tagged PI3K mutants in lysates from the above panel, using
antibodies against FLAG-tagged and HA epitopes, respectively. NS
indicates nonspecific band in the same blot. Results shown are repre-
sentative of two experiments. C, cells were pretreated with specific
inhibitors PD098059, SB203580, and LY294002 (20 mM each) for 1 h
before HRG treatment for 16 h. Quantitation of CAT activity is shown
as fold induction of CAT reporter activity by HRG treatment over the
control culture in each inhibitor.
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The results indicated that 2393 to 2314 region contained the
regulatory elements that may confer the HRG-mediated induc-
tion of EF-1a. Analysis of the transcription factor sites present
in the 2393 to 2314 revealed presence of an SP1 site. Recently
it was shown that HRG regulate the activity of SP1 transcrip-
tion factor (47). To verify the potential involvement of the SP1
site in HRG induction of EF-1a promoter, we next mutated the
SP1 site at 2369 to 2363 (construct 11). Point mutation of the
SP1 site completely abolished the HRG-mediated induction of
the construct containing 2393 to 2314 region. Mutation of
another region other than Sp1 site has no effect on HRG-
mediated induction (construct 10), suggesting a role of SP1 in
the HRG regulation of EF-1a promoter. Interestingly, con-
struct 8 (2393 to 2204), which contains two Sp1 sites, demon-
strated a significantly higher HRG-inducible activity (4-fold)
than the construct containing 2393 to 2314 (construct number
10) with one SP1 site (2.1-fold). Together, these observations
suggested a role of SP1 site in the observed HRG-mediated
regulation of EF-1a promoter.
Involvement of Histone Acetylation in HRG Regulation of
EF-1a—The eukaryotic genome is compacted with histone and
other proteins to form chromatin, which consists of repeating
units of nucleosomes (48, 49). For transcription factors to ac-
cess DNA, the repressive chromatin structure needs to be re-
modeled. Dynamic alterations in the chromatin structure can
facilitate or suppress the access of the transcription factors to
nucleosomal DNA, leading to transcription regulation. One
way to achieve this is through alterations in the acetylation
state of nucleosomal histones. Hyperacetylated chromatin is
generally associated with transcription activation, whereas hy-
poacetylated chromatin is associated with transcriptional re-
pression (48, 49). To investigate whether the HRG regulation of
EF-1a expression involves histone acetylation on the EF-1a
gene, we next performed chromatin immunoprecipitation
(ChIP) assay of the target gene, i.e. EF-a around a target
sequence in the promoter (2535 to 2209) which has multiple
SP1 sites by using antibodies specific for acetylated forms of H3
and H4. Representative results from several independent ex-
periments are shown in Fig. 8. HRG treatment of MCF-7 cells
was accompanied by a significant enhancement in the associ-
ation of EF-1a promoter region with the acetylated histones H3
and H4 (5.0- and 3.5-fold induction of associated-acetylated H3
and -acetylated H4 by HRG as compared with untreated cells).
In addition, there was also easily detectable levels of EF-1a
promoter association with the acetylated H3 and H4 in control
untreated cells (Fig. 8, lanes 1 and 3), implying a potential role
of histone acetylation in the base-line expression of EF-1a.
FIG. 8. Acetylation of histone H3 and histone H4 at the identi-
fied multiple SP1 sites by chromatin immunoprecipitation as-
say. A, schematic representation of EF-1a promoter sequence used for
in vivo chromatin association. B, MCF-7 cells were treated with (lanes
2 and 4) or without (lanes 1 and 3) HRG (30 ng/ml for 16 h), and
chromatin lysates were immunoprecipitated with antibodies against
acetylated H3 (lanes 1 and 2) or acetylated H4 (lanes 3 and 4), and
samples were processed as described under “Experimental Procedures.”
The top panel shows the PCR analysis of the input DNA. The middle
panel demonstrates the PCR analysis of 326 base pairs of EF-1a DNA
fragment associated with acetylated histone H3 or H4. Quantitation of
signals in the bottom panel is presented as fold induction over control
untreated cells. IP, immunoprecipitation. Results are representative of
three independent experiments.
FIG. 7. A role of SP1 in HRG Regulation of EF-1a promoter. A, deletion constructs were made as described under “Experimental
Procedures.” Fold of induction by HRG over untreated control cells is shown in the right-hand columns. Construct numbers 10–12 have similar
sequence, except that number 10 is wild type and has one Sp1 site at 2379 to 2374 position; construct number 11 was mutated nonspecifically at
2387 to 2385 where CCC were replaced with AGA, and construct number 12 was mutated at Sp1 site at 2391 to 2389 where CGC were replaced
with 59 TTA 39. B, regulation of EF-1a deletion constructs by HRG (16 h). Results shown are representative of three experiments.
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Earlier reports have shown a close correlation of up-regulation
of histone H3 and H4 acetylation with an increased transcrip-
tional activity (48, 49). In brief, our findings clearly demon-
strated the involvement of histone acetylation in HRG-medi-
ated stimulation of EF-a gene expression.
In summary, we have presented new evidence that treat-
ment of tumor cells with growth factors significantly increases
EF-1a promoter activity and mRNA and protein expression
and that HRG increases the acetylation of H3 and H4 on the
EF-1a promoter. Since constitutive EF-1a expression was not
well correlated with EGFR or HER2 overexpression in different
cell types, ligand-activated cellular pathways, rather than re-
ceptor levels, may be significant in the regulation of EF-1a
expression. These views are supported by a recent report show-
ing no effect of EGFR and HER2 overexpression on levels of
related EF-1d in human keratinocytes (50). However, despite
the lack of correlation with receptor levels, the ligand-induced
up-regulation of EF-1a expression was mediated by a specific
ligand-receptor interaction, as the anti-receptor blocking anti-
bodies C225 and herceptin could effectively reduce it. Our
study also shows the potential roles of MEK and p38MAPK in
the constitutive regulation of EF-1a promoter activity.
There are a number of possible functional implications for
growth factor-regulated EF-1a expression as follows: 1) promo-
tion of polypeptide elongation and thus potential contribution
to increased translation of mRNA encoding growth-related pro-
teins; 2) increased reorganization of the cytoskeleton, since it is
one of the earliest phenotypic responses of most cells to growth
factors and since EF-1a regulates actin bundling; 3) potential
undefined roles in the nucleus, due to the ability of EF-1a to
form a complex with ZPR1 (30). In summary, our findings have
clearly demonstrated for the first time a potential role of EF-1a
in the actions of HER growth factors that are widely deregu-
lated in human cancers and that ligand-dependent EF-1a ex-
pression was effectively inhibited with humanized anti-recep-
tor blocking antibodies C225 and herceptin. In addition, we
also provide new evidence to suggest that HRG stimulation of
EF-1a promoter requires the SP1 site and that the EF-1a
promoter undergoes histone acetylation in response to HRG.
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